Corient Private Wealth
TEVA icon

Corient Private Wealth’s Teva Pharmaceuticals TEVA Stock Holding History

Corient Private Wealth’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.75M Buy
51,726
+62
+0.1% +$2.06K ﹤0.01% 1472
2026
Q1 		$1.44M Buy
51,664
+2,601
+5% +$83.7K ﹤0.01% 1441
2025
Q4 		$1.53M Buy
49,063
+10,843
+28% +$267K ﹤0.01% 1282
2025
Q3 		$772K Sell
38,220
-1,320
-3% -$23.2K ﹤0.01% 1548
2025
Q2 		$663K Sell
39,540
-5,590
-12% -$90.2K ﹤0.01% 1555
2025
Q1 		$694K Sell
45,130
-11,720
-21% -$209K ﹤0.01% 1445
2024
Q4 		$1.25M Sell
56,850
-11,425
-17% -$208K ﹤0.01% 1214
2024
Q3 		$1.23M Sell
68,275
-21,458
-24% -$376K ﹤0.01% 1305
2024
Q2 		$1.46M Buy
89,733
+34,983
+64% +$539K ﹤0.01% 1174
2024
Q1 		$773K Sell
54,750
-69,086
-56% -$871K ﹤0.01% 1423
2023
Q4 		$1.29M Sell
123,836
-2,499
-2% -$23.3K ﹤0.01% 1188
2023
Q3 		$1.29M Buy
126,335
+56,683
+81% +$528K ﹤0.01% 1104
2023
Q2 		$524K Sell
69,652
-19,813
-22% -$161K ﹤0.01% 1430
2023
Q1 		$792K Buy
89,465
+19,500
+28% +$193K ﹤0.01% 1184
2022
Q4 		$638K Buy
+69,965
New +$610K ﹤0.01% 1064

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Corient Private Wealth's TEVA Position: Q2 2026 in Review

Corient Private Wealth increased its Teva Pharmaceuticals (TEVA) stake by 0.12% in Q2 2026, buying an estimated $2.06K and bringing the position to 51,726 shares worth $1.75M. The position accounts for ﹤0.01% of the portfolio, ranked #1472.

Corient Private Wealth first reported a position in TEVA in Q4 2022 and has held it in 15 quarters since. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Corient Private Wealth held 51,726 shares of Teva Pharmaceuticals worth $1.75M as of Q2 2026.
  • Corient Private Wealth bought 62 Teva Pharmaceuticals shares in Q2 2026, an estimated $2.06K.
  • Teva Pharmaceuticals made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #1472 holding.
  • Corient Private Wealth first reported a position in Teva Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.